SCHEMBL634467

SCHEMBL634467

N#Cc1ccc(N)c(C(=O)O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.57
KMT2A Q03164 2/20 0.57
GFER P55789 1/20 0.57
RXFP1 Q9HBX9 1/20 0.57
MCL1 Q07820 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
MEN1 O00255 1/20 0.55
USP2 O75604 1/20 0.55
POLB P06746 1/20 0.55
MAPT P10636 1/20 0.55
THRB P10828 1/20 0.55
PKM P14618 1/20 0.55
APEX1 P27695 1/20 0.55
RECQL P46063 1/20 0.55
BLM P54132 1/20 0.55
GLA P06280 1/20 0.53
KEAP1 Q14145 1/20 0.53
ALDH1A1 P00352 3/20 0.52
CDC25B P30305 1/20 0.52
CASP6 P55212 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2312770 0.85 IKBKB (0.49) KDM4EKMT2AGFERRXFP1MCL1
SCHEMBL3609438 0.85 XDH (0.49) KDM4EKMT2AGFERRXFP1MCL1
SCHEMBL1482937 0.84 KDM4E (0.67) KDM4EKMT2AGFERRXFP1MCL1
SCHEMBL14739736 0.83 ALDH1A1 (0.40) KDM4EKMT2AGFERRXFP1MCL1
SCHEMBL4852724 0.82 MAPT (0.58) KDM4EKMT2AMEN1USP2POLB
SCHEMBL3157619 0.82 XDH (0.53) KMT2ATDP1MEN1POLBALDH1A1
SCHEMBL22637148 0.81 KDM4E (0.57) KDM4EKMT2AGFERRXFP1MCL1
SCHEMBL9043331 0.79 RAB9A (0.42) KDM4EKMT2AGFERRXFP1POLB
SCHEMBL4842734 0.79 ALDH1A1 (0.57) KDM4ERXFP1POLBMAPTGLA
SCHEMBL2033094 0.79 BRAF (0.42) KDM4EKMT2AMEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025043563-A1 PEPTIDE TARGETING SOMATOSTATIN RECEPTOR, DRUG CONJUGATE AND USE THEREOF 主流源生物科技(上海)有限公司 2025-03-06 WO claimed
CN-122036604-A Compound and application thereof 中国药科大学 2026-05-15 CN disclosed
WO-2026099895-A1 PROCESS FOR PREPARING 2-AMINO-5-CYANOBENZOIC ACID DERIVATIVES PI INDUSTRIES LTD. (IN) 2026-05-15 WO disclosed
WO-2026099895-A1 PROCESS FOR PREPARING 2-AMINO-5-CYANOBENZOIC ACID DERIVATIVES PI INDUSTRIES LTD. (IN) 2026-05-15 WO disclosed
US-20250154152-A1 INHIBITORS OF NAEGLERIA FOWLERI CLEMSON UNIVERSITY 2025-05-15 US disclosed
CN-119977893-A Preparation method and application of sulfonamide compound for antagonizing NOD1 清华大学 2025-05-13 CN disclosed
WO-2025056012-A1 NEUTROPHIL ELASTASE INHIBITOR AND USE THEREOF 上海壹迪生物技术有限公司 2025-03-20 WO disclosed
CN-119638624-A Neutrophil elastase inhibitor and application thereof 上海壹迪生物技术有限公司 2025-03-18 CN disclosed
WO-2025043563-A1 PEPTIDE TARGETING SOMATOSTATIN RECEPTOR, DRUG CONJUGATE AND USE THEREOF 主流源生物科技(上海)有限公司 2025-03-06 WO disclosed
CN-116731017-B Quinoline and piperidine compound as well as preparation method and application thereof 海南大学 2024-10-01 CN disclosed
WO-2000076970-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2000-12-21 WO disclosed
WO-2000077027-A2 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2000-12-21 WO disclosed
EP-0686625-B1 ANTHRANILIC ACID DERIVATIVE EISAI CO LTD (JP) 1999-05-26 EP disclosed
EP-0912559-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-05-06 EP disclosed
US-5716993-A PHOSPHODIESTERASE ENZYME INHIBITOR FOR TREATING CARDIOVASCULAR DISORDER, ANGINA PECTORIS, HYPERTENSION, ASTHMA EISAI CO., LTD. (JP) 1998-02-10 US disclosed
WO-1998002434-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1998-01-22 WO disclosed
CN-1118595-A Anthranilic acid derivative EISAI CO LTD (JP) 1996-03-13 CN disclosed
EP-0686625-A1 ANTHRANILIC ACID DERIVATIVE Eisai Co., Ltd. (JP) 1995-12-13 EP disclosed
US-4026931-A AZO DYES, FIBER-REACTIVE; INDOLE OR 5-AMINO-PYRAZOLE COUPLING COMPONENT BAYER AKTIENGESELLSCHAFT (DT) 1977-05-31 US disclosed
US-3993619-A AZO DYES BAYER AKTIENGESELLSCHAFT (DT) 1976-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154152-A1 INHIBITORS OF NAEGLERIA FOWLERI SERPINB1, NAMPT, NIT2 KDM4E 4091/4885KMT2A 4367/4885GFER 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.